ANALISIS DRUG RELATED PROBLEMS PENGGUNAAN ANTIPSIKOTIK PADA PENDERITA GANGGUAN BIPOLAR DI RUMAH SAKIT JIWA “X” SURABAYA
Abstract Views:
684 times
PDF - FULL TEXT Downloads:
1239 times
Abstract
Abstrak - Gangguan bipolar adalah suatu gangguan yang disertai satu atau lebih episode hipomanik atau manik dimana episode tersebut sering digantikan dengan episode depresi mayor dengan jeda berupa periode mood yang normal. Pengobatan yang diterima oleh penderita gangguan bipolar dapat menimbulkan suatu permasalahan sehingga perlu pemantauan mengenai terapi penderita gangguan bipolar tersebut. Penelitian ini dilakukan untuk menganalisis drug related problems (DRPs) yang mungkin terjadi terkait penggunaan antipsikotik pada penderita yang pernah didiagnosis mengalami gangguan bipolar. Penelitian non-eksperimental ini dilakukan dengan rancangan analisis diskriptif yang bersifat retrospektif. Sebagai bahan penelitian digunakan data rekam medis sebanyak 30 sampel yang merupakan keseluruhan populasi selama bulan Januari 2013 sampai Oktober 2015. Berdasarkan hasil analisis data diperoleh DRPs yang sering terjadi adalah masalah terkait pemilihan obat yang kurang tepat untuk pasien dan juga termasuk kontraindikasi dengan pasien (45,92%), dan masalah interaksi obat yang dapat meningkatkan timbulnya reaksi obat yang tidak dikehendaki (25,51%). Masalah-masalah yang dijumpai tersebut bersifat potensial dan aktual.
Kata kunci: Antipsikotik, Gangguan Bipolar, Drug Related Problems
Abstract – Bipolar disorder is disorder accompanied by one or more episodes of hypomanic or manic which this episode is often replaced with a major depressive episode with periods of respite in the form of normal mood. Therapy which received by patients with bipolar disorder can causes some problems so that needs to be monitoring of their therapy. This study was done to analyze drug related problems that may occur related to the use of antipsychotics in patients who had been diagnosed with bipolar disorder. Non-experimental study was done with design descriptive retrospective analysis. This study used 30 medical records of patients with bipolar disorder period 30 January 2013 to October 2015. Based on the analysis of data obtained frequently DRPs are problems related to the selection of the drug, inappropriate drug (include contraindicated) (45,92%) and problems related to inappropriate combination of drugs, include drug interactions (25,51%). That problems are potential and actual.
Keywords: Antipsychotics, Bipolar Disorder, Drug Related Problems
Downloads
References
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, 2013, Riset Kesehatan Dasar 2013, 127-129.
Baxter K, 2010, Antipsychotics, Anxiolytics and Hypnotics in Stockley’s Drug Interactions, 9th edition, Pharmaceutical Press, London, Chapter 20, 831-912.
Departemen Farmakologi Fakultas Kedokteran Universitas Indonesia, 2010, Farmakologi dan Terapi, Jakarta: Gaya Baru.
Department of Veterans Affairs and Departement of Defense, 2010, Management of Bipolar Disorder in Adult (BD), 1-58.
Direktorat Bina Pelayanan Kesehatan Jiwa, Direktorat Jenderal Bina Pelayanan Medik, Departemen Kesehatan Republik Indonesia, 2009, Pedoman Terapi Psikofarmaka, 16-39.
Early Psychosis Prevention and Intervention Centre, 2006, What Is Psychosis?, (online), (http://www.eppic.org.au diakses 05-05-2015).
Endang, L, 2013, Aksi Obat Basis Farmakologi Klinis, 13th ed, Sandira Surabaya, Surabaya, 116-120.
Israr Y A, 2009, Gangguan Afektif Bipolar, Pekanbaru, Fakultas Farmasi Universitas Riau, (online), (http://www.Files-of-DrsMed.tk diakses 23-08-2015).
Kennedy N, Boydell J, et al, 2005, Gender Differences in Incidence and Age at Onsetof Manis and Bipolar Disorde Over a 35-YearPeriod in Camberwell, England, AmJ Psychiatry 2005; 162:257–262.
Maslim R, 2013, Diagnosis Gangguan Jiwa, 2nd ed, Bagian Ilmu Kedokteran Jiwa FK-Unika Atma Jaya, Jakarta, 60-63.
Maslim R, 2014, Penggunaan Klinis Obat Psikotropik, Bagian Ilmu Kedokteran Jiwa FK-Unika Atma Jaya, Jakarta, 16-39.
National Institute for Health and Care Excellence, 2014, Bipolar Disorder:Assesment and Management, 7-46.
National Institute of Mental Health, 2012, Bipolar Disorder in Adults, No. publikasi 12-3679: 1-16.
Nevid J S, Rathus S A, Greene B, 2003, Psikologi Abnormal, 5thed, Murad J, dkk, 2005, Jakarta, Erlangga, 228-270.
Pharmaceutical Care Network Europe, 2010, Classification for Drug Related Problems, 2-5.
Syafwan A F, Kurniawan S, Asterina, 2014, Gambaran Peningkatan Angka Kejadian Gangguan Afektif Bipolar dengan Gejala Psikotik pada Pasien Rawat Inap di RSJ Prof. Dr. HB. Sa’anin Padang padaTahun 2010-2011, Vol. 3 No. 2.
Thorp C M, 2008, Affective Disorders and Drug Used to TreatBipolar Depression and Mania in Pharmacology for The Health Care Profession, 1st edition, Wiley Blackwell, Oxford, Chapter 11, 194-201.
Wijono R, et al, 2013, Gambaran dan Karakteristik Penggunaan Triheksifenidil pada Pasien yang Mendapat Terapi Antipsikotik, Vol. 63 No. 1.
Yatham L N, Kennedy S H, et al, 2013, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Collaborative Update of CANMAT Guidelines for the Management of Patients with Bipolar Disorder, 15: 1-44.
- Articles published in CALYPTRA are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to CALYPTRA to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in CALYPTRA, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
